Treatment of genitourinary tract disorders
OwnerPaul Ashton, Grazyna Cynkowska +2inventors
InventorsPaul Ashton, Grazyna Cynkowska, Tadeusz Cynkowski, Thomas J. Smith
Life of this patent
Estimating the term…
Abstract
Genitourinary system disorders are treated with therapeutic agents, and optionally further with radiation treatments.
Claims37
A drug delivery device comprising a codrug, a pharmaceutically acceptable salt, or prodrug thereof, for administration of at least one biologically active moiety, which codrug comprises:
- a) at least two constituent moieties, each moiety being a residue of a biologically active compound or a prodrug thereof, including a first constituent moiety and a second constituent moiety;
- and
- b) a linkage covalently linking said at least two constituent moieties to form said codrug, said linkage is cleaved under physiological conditions to regenerate said constituent moieties;
- wherein the device is dimensioned to position two radiation seeds a predetermined distance apart.
A method for treating a patient, comprising implanting a drug delivery device comprising a codrug, a pharmaceutically acceptable salt, or prodrug thereof, for administration of at least one biologically active moiety, which codrug comprises:
- a) at least two constituent moieties, each moiety being a residue of a biologically active compound or a prodrug thereof, including a first constituent moiety and a second constituent moiety;
- and
- b) a linkage covalently linking said at least two constituent moieties to form said codrug, said linkage is cleaved under physiological conditions to regenerate said constituent moieties;
- wherein the device is implanted in the prostate, cervix, bladder, bladder neck, anal submucosa, or the tissues surrounding the aforementioned tissues or organs.
A method of inhibiting cell proliferation in a patient in need of treatment, comprising implanting a drug delivery device comprising a codrug, a pharmaceutically acceptable salt, or prodrug thereof, for administration of at least one biologically active moiety, which codrug comprises:
- a) at least two constituent moieties, each moiety being a residue of a biologically active compound or a prodrug thereof, including a first constituent moiety and a second constituent moiety;
- and
- b) a linkage covalently linking said at least two constituent moieties to form said codrug, said linkage is cleaved under physiological conditions to regenerate said constituent moieties;
- wherein the device includes a therapeutically effective amount of a codrug, or a pharmaceutically acceptable salt thereof.
A method of inhibiting inflammation in a patient in need of treatment, comprising implanting a drug delivery device comprising a codrug, a pharmaceutically acceptable salt, or prodrug thereof, for administration of at least one biologically active moiety, which codrug comprises:
- a) at least two constituent moieties, each moiety being a residue of a biologically active compound or a prodrug thereof, including a first constituent moiety and a second constituent moiety;
- and
- b) a linkage covalently linking said at least two constituent moieties to form said codrug, said linkage is cleaved under physiological conditions to regenerate said constituent moieties;
- wherein the device includes a therapeutically effective amount of a codrug, or a pharmaceutically acceptable salt thereof.
A method of manufacturing a drug delivery device, comprising providing forming a codrug comprising
- a) at least two constituent moieties, each moiety being a residue of a biologically active compound or a prodrug thereof, including a first constituent moiety and a second constituent moiety;
- and
- b) a linkage covalently linking said at least two constituent moieties to form said codrug, said linkage is cleaved under physiological conditions to regenerate said constituent moieties;
- wherein the device is dimensioned to position two radiation seeds a predetermined distance apart.
Dependencies are inferred from the claim text.